Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Viral Load Measurement
2.3. IFN-γ ELISpot Assays
2.4. CMV Antigens
2.5. Total CD8+ T Cell Count Determination
2.6. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. Measurement of CMV-Specific Cellular Immunity in Response to CMV Proteins and Peptides
3.3. Monitoring of Immune Parameters and Clinical Complications in Patient No. 12
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- De la Cámara, R. CMV in Hematopoietic Stem Cell Transplantation. Mediterr. J. Hematol. Infect. Dis. 2016, 8, e2016031. [Google Scholar] [CrossRef] [Green Version]
- Lilleri, D.; Gerna, G. Strategies to Control Human Cytomegalovirus Infection in Adult Hematopoietic Stem Cell Transplant Recipients. Immunotherapy 2016, 8, 1135–1149. [Google Scholar] [CrossRef] [PubMed]
- Ljungman, P.; de la Camara, R.; Robin, C.; Crocchiolo, R.; Einsele, H.; Hill, J.A.; Hubacek, P.; Navarro, D.; Cordonnier, C.; Ward, K.N.; et al. Guidelines for the Management of Cytomegalovirus Infection in Patients with Haematological Malignancies and after Stem Cell Transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect. Dis. 2019, 19, e260–e272. [Google Scholar] [CrossRef]
- Wagner-Drouet, E.; Teschner, D.; Wolschke, C.; Janson, D.; Schäfer-Eckart, K.; Gärtner, J.; Mielke, S.; Schreder, M.; Kobbe, G.; Kondakci, M.; et al. Standardized Monitoring of Cytomegalovirus-Specific Immunity Can Improve Risk Stratification of Recurrent Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation. Haematologica 2021, 106, 363–374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nesher, L.; Shah, D.P.; Ariza-Heredia, E.J.; Azzi, J.M.; Siddiqui, H.K.; Ghantoji, S.S.; Marsh, L.Y.; Michailidis, L.; Makedonas, G.; Rezvani, K.; et al. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. J. Infect. Dis. 2016, 213, 1701–1707. [Google Scholar] [CrossRef]
- Boeckh, M.; Leisenring, W.; Riddell, S.R.; Bowden, R.A.; Huang, M.-L.; Myerson, D.; Stevens-Ayers, T.; Flowers, M.E.D.; Cunningham, T.; Corey, L. Late Cytomegalovirus Disease and Mortality in Recipients of Allogeneic Hematopoietic Stem Cell Transplants: Importance of Viral Load and T-Cell Immunity. Blood 2003, 101, 407–414. [Google Scholar] [CrossRef]
- Avetisyan, G.; Aschan, J.; Hägglund, H.; Ringdén, O.; Ljungman, P. Evaluation of Intervention Strategy Based on CMV-Specific Immune Responses after Allogeneic SCT. Bone Marrow Transplant. 2007, 40, 865–869. [Google Scholar] [CrossRef] [Green Version]
- Chemaly, R.F.; El Haddad, L.; Winston, D.J.; Rowley, S.D.; Mulane, K.M.; Chandrasekar, P.; Avery, R.K.; Hari, P.; Peggs, K.S.; Kumar, D.; et al. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. Clin. Infect. Dis. 2020, 71, 2365–2374. [Google Scholar] [CrossRef]
- El Haddad, L.; Ariza-Heredia, E.; Shah, D.P.; Jiang, Y.; Blanchard, T.; Ghantoji, S.S.; El Chaer, F.; El-Haddad, D.; Prayag, A.; Nesher, L.; et al. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. J. Infect. Dis. 2019, 219, 898–907. [Google Scholar] [CrossRef]
- Yong, M.K.; Lewin, S.R.; Manuel, O. Immune Monitoring for CMV in Transplantation. Curr. Infect. Dis. Rep. 2018, 20, 4. [Google Scholar] [CrossRef]
- Ciáurriz, M.; Zabalza, A.; Beloki, L.; Mansilla, C.; Pérez-Valderrama, E.; Lachén, M.; Bandrés, E.; Olavarría, E.; Ramírez, N. The Immune Response to Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Cell. Mol. Life Sci. CMLS 2015, 72, 4049–4062. [Google Scholar] [CrossRef]
- Barabas, S.; Spindler, T.; Kiener, R.; Tonar, C.; Lugner, T.; Batzilla, J.; Bendfeldt, H.; Rascle, A.; Asbach, B.; Wagner, R.; et al. An Optimized IFN-γ ELISpot Assay for the Sensitive and Standardized Monitoring of CMV Protein-Reactive Effector Cells of Cell-Mediated Immunity. BMC Immunol. 2017, 18, 14. [Google Scholar] [CrossRef] [Green Version]
- Banas, B.; Steubl, D.; Renders, L.; Chittka, D.; Banas, M.C.; Wekerle, T.; Koch, M.; Witzke, O.; Mühlfeld, A.; Sommerer, C.; et al. Clinical Validation of a Novel ELISpot-Based in Vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients: A Multicenter, Longitudinal, Prospective, Observational Study. Transpl. Int. 2018, 31, 436–450. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Banas, B.; Böger, C.A.; Lückhoff, G.; Krüger, B.; Barabas, S.; Batzilla, J.; Schemmerer, M.; Köstler, J.; Bendfeldt, H.; Rascle, A.; et al. Validation of T-Track® CMV to Assess the Functionality of Cytomegalovirus-Reactive Cell-Mediated Immunity in Hemodialysis Patients. BMC Immunol. 2017, 18, 15. [Google Scholar] [CrossRef] [Green Version]
- Jarque, M.; Crespo, E.; Melilli, E.; Gutiérrez, A.; Moreso, F.; Guirado, L.; Revuelta, I.; Montero, N.; Torras, J.; Riera, L.; et al. Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial. Clin. Infect. Dis. 2020, 71, 2375–2385. [Google Scholar] [CrossRef] [PubMed]
- Jarque, M.; Melilli, E.; Crespo, E.; Manonelles, A.; Montero, N.; Torras, J.; Cruzado, J.M.; Luque, S.; Gil-Vernet, S.; Grinyó, J.M.; et al. CMV-Specific Cell-Mediated Immunity at 3-Month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-Onset CMV Infection Regardless the Type of Induction Therapy. Transplantation 2018, 102, e472–e480. [Google Scholar] [CrossRef]
- Chanouzas, D.; Small, A.; Borrows, R.; Ball, S. Assessment of the T-SPOT.CMV Interferon-γ Release Assay in Renal Transplant Recipients: A Single Center Cohort Study. PLoS ONE 2018, 13, e0193968. [Google Scholar] [CrossRef] [Green Version]
- Kumar, D.; Chin-Hong, P.; Kayler, L.; Wojciechowski, D.; Limaye, A.P.; Osama Gaber, A.; Ball, S.; Mehta, A.K.; Cooper, M.; Blanchard, T.; et al. A Prospective Multicenter Observational Study of Cell-Mediated Immunity as a Predictor for Cytomegalovirus Infection in Kidney Transplant Recipients. Am. J. Transplant. 2019, 19, 2505–2516. [Google Scholar] [CrossRef]
- Neefjes, J.; Jongsma, M.L.M.; Paul, P.; Bakke, O. Towards a Systems Understanding of MHC Class I and MHC Class II Antigen Presentation. Nat. Rev. Immunol. 2011, 11, 823–836. [Google Scholar] [CrossRef] [PubMed]
- Colbert, J.D.; Cruz, F.M.; Rock, K.L. Cross-Presentation of Exogenous Antigens on MHC I Molecules. Curr. Opin. Immunol. 2020, 64, 1–8. [Google Scholar] [CrossRef]
- Luft, T.; Rizkalla, M.; Tai, T.Y.; Chen, Q.; MacFarlan, R.I.; Davis, I.D.; Maraskovsky, E.; Cebon, J. Exogenous Peptides Presented by Transporter Associated with Antigen Processing (TAP)-Deficient and TAP-Competent Cells: Intracellular Loading and Kinetics of Presentation. J. Immunol. 2001, 167, 2529–2537. [Google Scholar] [CrossRef] [Green Version]
- Barabas, S.; Gary, R.; Bauer, T.; Lindner, J.; Lindner, P.; Weinberger, B.; Jilg, W.; Wolf, H.; Deml, L. Urea-Mediated Cross-Presentation of Soluble Epstein-Barr Virus BZLF1 Protein. PLoS Pathog. 2008, 4, e1000198. [Google Scholar] [CrossRef]
- Körber, N.; Behrends, U.; Protzer, U.; Bauer, T. Evaluation of T-Activated Proteins as Recall Antigens to Monitor Epstein-Barr Virus and Human Cytomegalovirus-Specific T Cells in a Clinical Trial Setting. J. Transl. Med. 2020, 18, 242. [Google Scholar] [CrossRef] [PubMed]
- Hobeika, A.C.; Morse, M.A.; Osada, T.; Ghanayem, M.; Niedzwiecki, D.; Barrier, R.; Lyerly, H.K.; Clay, T.M. Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood: A Comparison of Peptide MHC Tetramer, ELISpot, and Intracellular Cytokine Analysis. J. Immunother. 2005, 28, 63–72. [Google Scholar] [CrossRef]
- Slezak, S.L.; Bettinotti, M.; Selleri, S.; Adams, S.; Marincola, F.M.; Stroncek, D.F. CMV Pp65 and IE-1 T Cell Epitopes Recognized by Healthy Subjects. J. Transl. Med. 2007, 5, 17. [Google Scholar] [CrossRef] [Green Version]
- Ameres, S.; Liang, X.; Wiesner, M.; Mautner, J.; Moosmann, A. A Diverse Repertoire of CD4 T Cells Targets the Immediate-Early 1 Protein of Human Cytomegalovirus. Front. Immunol. 2015, 6, 598. [Google Scholar] [CrossRef] [Green Version]
- Chevalier, M.F.; Bobisse, S.; Costa-Nunes, C.; Cesson, V.; Jichlinski, P.; Speiser, D.E.; Harari, A.; Coukos, G.; Romero, P.; Nardelli-Haefliger, D.; et al. High-Throughput Monitoring of Human Tumor-Specific T-Cell Responses with Large Peptide Pools. Oncoimmunology 2015, 4, e1029702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Valentine, L.E.; Piaskowski, S.M.; Rakasz, E.G.; Henry, N.L.; Wilson, N.A.; Watkins, D.I. Recognition of Escape Variants in ELISPOT Does Not Always Predict CD8+ T-Cell Recognition of Simian Immunodeficiency Virus-Infected Cells Expressing the Same Variant Sequences. J. Virol. 2008, 82, 575–581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yokomaku, Y.; Miura, H.; Tomiyama, H.; Kawana-Tachikawa, A.; Takiguchi, M.; Kojima, A.; Nagai, Y.; Iwamoto, A.; Matsuda, Z.; Ariyoshi, K. Impaired Processing and Presentation of Cytotoxic-T-Lymphocyte (CTL) Epitopes Are Major Escape Mechanisms from CTL Immune Pressure in Human Immunodeficiency Virus Type 1 Infection. J. Virol. 2004, 78, 1324–1332. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bennett, M.S.; Ng, H.L.; Dagarag, M.; Ali, A.; Yang, O.O. Epitope-Dependent Avidity Thresholds for Cytotoxic T-Lymphocyte Clearance of Virus-Infected Cells. J. Virol. 2007, 81, 4973–4980. [Google Scholar] [CrossRef] [Green Version]
- Hakki, M.; Riddell, S.R.; Storek, J.; Carter, R.A.; Stevens-Ayers, T.; Sudour, P.; White, K.; Corey, L.; Boeckh, M. Immune Reconstitution to Cytomegalovirus after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Host Factors, Drug Therapy, and Subclinical Reactivation. Blood 2003, 102, 3060–3067. [Google Scholar] [CrossRef] [Green Version]
- Ogonek, J.; Varanasi, P.; Luther, S.; Schweier, P.; Kühnau, W.; Göhring, G.; Dammann, E.; Stadler, M.; Ganser, A.; Borchers, S.; et al. Possible Impact of CMV-Specific CD8+ T-Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic SCT. Biol. Blood Marrow Transplant. 2017, 23, 1046–1053. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shams El-Din, A.A.; El-Desoukey, N.A.; Amin Tawadrous, D.G.; Fouad, N.M.B.E.-D.; Abdel-Mooti, M.; Hotar, S.F. The Potential Association of CMV-Specific CD8+ T Lymphocyte Reconstitution with the Risk of CMV Reactivation and Persistency in Post Allogeneic Stem Cell Transplant Patients. Hematology 2018, 23, 463–469. [Google Scholar] [CrossRef] [Green Version]
- Khan, N.; Cobbold, M.; Keenan, R.; Moss, P.A.H. Comparative Analysis of CD8+ T Cell Responses against Human Cytomegalovirus Proteins Pp65 and Immediate Early 1 Shows Similarities in Precursor Frequency, Oligoclonality, and Phenotype. J. Infect. Dis. 2002, 185, 1025–1034. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elkington, R.; Walker, S.; Crough, T.; Menzies, M.; Tellam, J.; Bharadwaj, M.; Khanna, R. Ex Vivo Profiling of CD8+-T-Cell Responses to Human Cytomegalovirus Reveals Broad and Multispecific Reactivities in Healthy Virus Carriers. J. Virol. 2003, 77, 5226–5240. [Google Scholar] [CrossRef] [Green Version]
- Lacey, S.F.; Villacres, M.C.; La Rosa, C.; Wang, Z.; Longmate, J.; Martinez, J.; Brewer, J.C.; Mekhoubad, S.; Maas, R.; Leedom, J.M.; et al. Relative Dominance of HLA-B*07 Restricted CD8+ T-Lymphocyte Immune Responses to Human Cytomegalovirus Pp65 in Persons Sharing HLA-A*02 and HLA-B*07 Alleles. Hum. Immunol. 2003, 64, 440–452. [Google Scholar] [CrossRef]
- Hackstein, H.; Thomson, A.W. Dendritic Cells: Emerging Pharmacological Targets of Immunosuppressive Drugs. Nat. Rev. Immunol. 2004, 4, 24–34. [Google Scholar] [CrossRef] [PubMed]
- Woltman, A.M.; de Fijter, J.W.; Kamerling, S.W.; Paul, L.C.; Daha, M.R.; van Kooten, C. The Effect of Calcineurin Inhibitors and Corticosteroids on the Differentiation of Human Dendritic Cells. Eur. J. Immunol. 2000, 30, 1807–1812. [Google Scholar] [CrossRef]
- Tajima, K.; Amakawa, R.; Ito, T.; Miyaji, M.; Takebayashi, M.; Fukuhara, S. Immunomodulatory Effects of Cyclosporin A on Human Peripheral Blood Dendritic Cell Subsets. Immunology 2003, 108, 321–328. [Google Scholar] [CrossRef]
- Solano, C.; Benet, I.; Remigia, M.J.; de la Cámara, R.; Muñoz-Cobo, B.; Costa, E.; Clari, M.Á.; Bravo, D.; Amat, P.; Navarro, D. Immunological Monitoring for Guidance of Preemptive Antiviral Therapy for Active Cytomegalovirus Infection in Allogeneic Stem-Cell Transplant Recipients: A Pilot Experience. Transplantation 2011, 92, e17–e20. [Google Scholar] [CrossRef]
- Ozdemir, E.; St John, L.S.; Gillespie, G.; Rowland-Jones, S.; Champlin, R.E.; Molldrem, J.J.; Komanduri, K.V. Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Is Associated with the Presence of Dysfunctional Antigen-Specific CD8+ T Cells. Blood 2002, 100, 3690–3697. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Study Population, n (%) | 15 (100%) |
---|---|
Gender, n (%) | |
Male | 8 (53.3%) |
Female | 7 (46.7%) |
Age in years, median (range) | 57 (29–70) |
Underlying disease, n (%) | |
Acute myeloid leukemia | 10 (66.7%) |
Acute lymphoid leukemia | 2 (13.3%) |
Non-Hodgkin’s lymphoma | 2 (13.3%) |
Severe aplastic anemia | 1 (6.7%) |
Donor (D)/Recipient (R) CMV serostatus, n (%) | |
D+/R+ | 4 (26.7%) |
D+/R− | 1 (6.6%) |
D−/R+ | 10 (66.7%) |
Stem cell source, n (%) | |
Bone marrow | 3 (20.0%) |
Peripheral blood | 12 (80.0%) |
Donor source, n (%) | |
Matched sibling | 4 (26.7%) |
Matched unrelated donor | 9 (60.0%) |
Mismatched unrelated donor | 2 (13.3%) |
Conditioning regimen, n (%) | |
Non-myeloablative | 3 (20.0%) |
Myeloablative, standard (MAC) | 9 (60.0%) |
Myeloablative, toxicity-reduced (RIC) | 3 (20.0%) |
At least one treatment-requiring CMV reactivation, n (%) | 10 (66.7%) |
CMV disease, n (%) | 1 (6.7%) |
Graft-versus-host disease (GvHD), n (%) | 6 (40.0%) |
Death, n (%) | 2 (13.3%) |
Results | Positive Concordance | Negative Concordance | Overall Concordance | |
---|---|---|---|---|
n | n | n | % | |
Overall ELISpot test Result a | 16 | 13 | 29 | 74.4% (29/39) |
IE-1 | 7 | 19 | 26 | 66.7% (26/39) |
pp65 | 13 | 22 | 35 | 89.7% (35/39) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wagner-Drouet, E.; Teschner, D.; Wolschke, C.; Schäfer-Eckart, K.; Gärtner, J.; Mielke, S.; Schreder, M.; Kobbe, G.; Hilgendorf, I.; Klein, S.; et al. Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation. Diagnostics 2021, 11, 312. https://doi.org/10.3390/diagnostics11020312
Wagner-Drouet E, Teschner D, Wolschke C, Schäfer-Eckart K, Gärtner J, Mielke S, Schreder M, Kobbe G, Hilgendorf I, Klein S, et al. Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation. Diagnostics. 2021; 11(2):312. https://doi.org/10.3390/diagnostics11020312
Chicago/Turabian StyleWagner-Drouet, Eva, Daniel Teschner, Christine Wolschke, Kerstin Schäfer-Eckart, Johannes Gärtner, Stephan Mielke, Martin Schreder, Guido Kobbe, Inken Hilgendorf, Stefan Klein, and et al. 2021. "Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation" Diagnostics 11, no. 2: 312. https://doi.org/10.3390/diagnostics11020312
APA StyleWagner-Drouet, E., Teschner, D., Wolschke, C., Schäfer-Eckart, K., Gärtner, J., Mielke, S., Schreder, M., Kobbe, G., Hilgendorf, I., Klein, S., Verbeek, M., Ditschkowski, M., Koch, M., Lindemann, M., Schmidt, T., Rascle, A., Barabas, S., Deml, L., Wagner, R., & Wolff, D. (2021). Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation. Diagnostics, 11(2), 312. https://doi.org/10.3390/diagnostics11020312